CRNX

Crinetics Pharmaceuticals Inc

84.95

Aug 31 • 3:59 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Mid NASD

Peers: RYTM BMRN NBIX AXSM KRYS MDGL MIRM ALNY INCY VKTX

| Held by: VTI VB VBK VXF VTWO VHT VTWG VT MNA VTHR

Index	-
Market Cap	9.01B
Enterprise Value	7.85B
Income	-501.61M
Sales	42.16M
Book/sh	11.27
Cash/sh	11.37
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	594
IPO	Jul 18, 2018

P/E	-
Forward P/E	-
PEG	-
P/S	213.70
P/B	7.54
P/C	7.47
P/FCF	-
EV/EBITDA	-
EV/Sales	186.22
Quick Ratio	15.53
Current Ratio	15.57
Debt/Eq	0.04
LT Debt/Eq	0.03
Option/Short	Yes / No

EPS (ttm)	-5.05
EPS next Y	-4.14
EPS next Q	-1.19
EPS this Y	4.98%
EPS next Y	11.91%
EPS next 5Y	16.23%
EPS past 3/5Y	-16.20% -15.33%
Sales past 3/5Y	17.56% -
EPS Y/Y TTM	-22.68%
Sales Y/Y TTM	2928.45%
EPS Q/Q	7.14%
Sales Q/Q	2336.28%
Earnings	Aug 03 AMC
EPS/Sales Surpr.	3.28% 69.24%

Insider Own	5.70%
Insider Trans	-2.30%
Inst Own	100.42%
Inst Trans	-
ROA	-38.42%
ROE	-42.45%
ROIC	-40.70%
Gross Margin	86.55%
Oper. Margin	-1302.52%
Profit Margin	-1189.88%
SMA20	0.50%
SMA50	13.52%
SMA200	68.41%
Trades

Shs Outstand	105.81M
Shs Float	101.81M
Short Float	6.47%
Short Ratio	1.63
Short Interest	6.59M
52W High	85.01 -0.07%
52W Low	31.00 174.03%
Volatility	0.08% 0.20%
ATR (14)	0.41
RSI (14)	89.79
Beta	0.02
Rel Volume	0.00
Avg Volume	4.04M
Volume	0

Perf Week	0.13%
Perf Month	1.23%
Perf Quarter	158.05%
Perf Half Y	122.21%
Perf YTD	82.49%
Perf Year	174.12%
Perf 3Y	390.47%
Perf 5Y	260.42%
Perf 10Y	-
Recom	3.00
Target Price	85.00
Prev Close	84.95
Price	84.95
Change %	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-02-26	Initiated	UBS	Buy	$55
Jan-12-26	Upgrade	Goldman	Neutral → Buy	$67
Jul-10-25	Initiated	Goldman	Neutral	$36
Mar-25-25	Initiated	Stifel	Buy	$60
Feb-11-25	Initiated	TD Cowen	Buy
Feb-04-25	Initiated	Wolfe Research	Peer Perform
Jan-22-25	Upgrade	Jefferies	Hold → Buy	$55
Mar-06-24	Initiated	Citigroup	Buy	$68
Jan-16-24	Initiated	Morgan Stanley	Overweight	$50
Dec-21-23	Initiated	Jefferies	Hold	$35
Nov-20-23	Resumed	JP Morgan	Overweight	$35
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight	$52 → $50
Aug-31-23	Initiated	Oppenheimer	Outperform	$40
Apr-24-23	Initiated	Piper Sandler	Overweight	$56
Mar-30-23	Initiated	Robert W. Baird	Outperform	$48
Nov-30-21	Initiated	JMP Securities	Mkt Outperform	$43
Nov-23-21	Initiated	Evercore ISI	Outperform	$68
Jun-18-21	Upgrade	JP Morgan	Neutral → Overweight	$28
Dec-23-19	Initiated	ROTH Capital	Buy	$37
Feb-14-19	Initiated	H.C. Wainwright	Buy	$35

Show Previous Ratings

Sep-01-26 11:07AM	Vertex Completes $10 Billion Crinetics Acquisition, Adding Rare Endocrine Growth Platform (InvestorsHub)
09:03AM	Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team (Business Wire)
Aug-17-26 09:16PM	Are DSGR, HLX, ATAI, CRNX Obtaining Fair Deals for their Shareholders? (PR Newswire)
Aug-06-26 10:31PM	Are UTZ, VEEE, CRNX Obtaining Fair Deals for their Shareholders? (PR Newswire)
Aug-04-26 08:30AM	Vertex Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary (Moby)
07:39PM	Loading…
Aug-03-26 07:39PM	Are ACA, CRNX, LEG Obtaining Fair Deals for their Shareholders? (PR Newswire)
04:05PM	Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
Jul-28-26 10:50AM	Are UTZ, CRNX, SOLS Obtaining Fair Deals for their Shareholders? (PR Newswire)
Jul-23-26 11:56AM	Nuvectis' NXP100 Just Achieved the First Marketing Approval Ever for a Once-Daily Oral Factor B Inhibitor (FinanceWire)
Jul-22-26 12:48PM	Vertex was sole bidder in high-premium Crinetics acquisition (BioPharma Dive)
10:34AM	What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin's Rare-Obesity Opportunity (FinanceWire)
Jul-21-26 02:51PM	Are CRNX, VEEE, NXTC, TCBK Obtaining Fair Deals for their Shareholders? (PR Newswire)
08:35AM	Biotech IPO Gains Crush AI Listings With Standout 55% Return (Bloomberg)
Jul-15-26 08:49AM	After Crinetics' $10 Billion Deal, Could Entera Bio Be the Next Category-Defining Oral Peptide Story? (FinanceWire)
Jul-14-26 04:09PM	Are CRNX, VEEE, ESI Obtaining Fair Deals for their Shareholders? (PR Newswire)
07:11PM	Loading…
Jul-09-26 07:11PM	Are ESI, CRNX, SOLS Obtaining Fair Deals for their Shareholders? (PR Newswire)
07:35AM	The Billion-Dollar Pill: With NXP100, Nuvectis Pharma Just Staked Its Claim in the New Biotech Gold Rush (FinanceWire)
Jul-08-26 01:11AM	VKTX Vs BCRX: Which Biotech Takeover Favorite Offers More Upside After Vertexs $10B CRNX Deal? (Stocktwits)
Jul-07-26 11:34PM	Why Did CRNX, D, BCRX Stocks Surge To 52-Week Highs Today? (Stocktwits) +98.74%
11:09PM	Why Crinetics Stock Doubled After Vertexs $10 Billion Buyout (BeInCrypto)
02:51PM	Vertex Pays $10 Billion to Enter Rare Endocrine Disease (GuruFocus.com)
09:59AM	Crinetics Acquisition Creates A Fifth Commercial Pillar For Vertex, Says Analyst Why HC Wainwright Sees A 24% Upside Potential In VRTX Stock (Stocktwits)
08:14AM	Vertex Pharmaceuticals buying Crinetics for $10 billion (Quartz)
07:40AM	Tech Weakness Resumes After Samsung Misses Lofty AI Expectations (Bloomberg)
07:33AM	This Biotech Stock Is Soaring 99% After Vertex Agrees to Takeover Deal (Barrons.com)
06:55AM	Vertex signs agreement to acquire Crinetics for $10bn (Pharmaceutical Technology)
Jul-06-26 08:07PM	CRNX Stock Soars Nearly 100% After-Hours On Vertex's $10B Acquisition (Stocktwits)
05:02PM	Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $10 Billion (The Wall Street Journal)
04:42PM	Crinetics soars on $10B acquisition by Vertex (Investing.com)
04:04PM	Vertex to Acquire Crinetics Pharmaceuticals (Business Wire)
04:05PM	Loading…
Jun-30-26 04:05PM	Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026 (GlobeNewswire)
Jun-14-26 04:30PM	Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026 (GlobeNewswire)
02:45PM	Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY (paltusotine) Provides Durable, Consistent Acromegaly Control (GlobeNewswire)
Jun-02-26 04:05PM	Crinetics and Leading Patient Groups Launch 'Everyday Advocacy' Initiative to Empower People Across Endocrine Disease Communities (GlobeNewswire) -5.53%
04:55AM	Crinetics' Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations (GlobeNewswire)
May-22-26 04:05PM	Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026 (GlobeNewswire)
May-08-26 08:30AM	Crinetics Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary (Moby) -13.82%
May-07-26 04:05PM	Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
Apr-27-26 05:13PM	Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY (Paltusotine) for the Treatment of Acromegaly in Adults (GlobeNewswire)
Apr-08-26 04:05PM	Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026 (GlobeNewswire)
Mar-26-26 04:05PM	Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify (Paltusotine) in Acromegaly (GlobeNewswire) -7.27%
Mar-08-26 08:04PM	Crinetics Pharmaceuticals Highlights Early PALSONIFY Sales, EU Milestone, and GPCR Pipeline at TD Cowen Conf. (MarketBeat)
Feb-27-26 08:30AM	Crinetics Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary (Moby) -6.04%
12:05AM	Crinetics Pharmaceuticals Inc (CRNX) Q4 2025 Earnings Call Highlights: Strong Product Launch ... (GuruFocus.com)
Feb-26-26 10:07PM	Crinetics Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
06:00PM	Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
04:05PM	Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Feb-18-26 07:37PM	Analysts Bullish on Crinetics (CRNX) Amid Positive Clinical Trial for New Drug (Insider Monkey)
Feb-05-26 04:05PM	Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March (GlobeNewswire) -5.57%
Jan-26-26 05:00PM	Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 (GlobeNewswire)
Jan-22-26 04:05PM	Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH) (GlobeNewswire)
03:09AM	Jim Cramer on Crinetics: "That's a Better Spec Than Aquestive" (Insider Monkey)
Jan-17-26 06:03AM	Markets Climb Wall-of-Worry: Oppenheimer Sees Resilience Driving 2026 and Suggests 2 Stocks to Buy (TipRanks)
Jan-15-26 11:35AM	Goldman Sachs Upgrades Crinetics Pharmaceuticals, Inc. (CRNX) To Buy From Neutral (Insider Monkey)
Jan-12-26 04:05PM	Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-06-26 09:22PM	Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock (GlobeNewswire) +16.08%
Jan-05-26 04:02PM	Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock (GlobeNewswire)
08:00AM	Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia (GlobeNewswire)
Jan-04-26 04:00PM	Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (GlobeNewswire)
Dec-19-25 07:55AM	Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines (PR Newswire) +6.36%
Dec-18-25 04:05PM	Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.35%
Dec-11-25 04:05PM	Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) (GlobeNewswire)
07:44AM	Crinetics Pharmaceuticals, Inc. (CRNX) Poised for Transformational Growth in 2026: Piper Sandler (Insider Monkey)
Dec-10-25 04:34PM	Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-03-25 08:00AM	Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors (GlobeNewswire)
Nov-20-25 04:05PM	Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome (GlobeNewswire)
Nov-10-25 04:28PM	Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-07-25 04:16PM	Why Crinetics Pharmaceuticals Stock Was Sliding on Friday (Motley Fool) -8.02%
Nov-06-25 05:20PM	Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Oct-23-25 08:00AM	Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting (GlobeNewswire)
Oct-10-25 04:41PM	Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-07-25 01:04PM	Cantor Fitzgerald Maintains a Buy Rating on Crinetics Pharmaceuticals (CRNX) (Insider Monkey)
Oct-06-25 04:05PM	Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 (GlobeNewswire)
Sep-30-25 11:49AM	JMP Backs Crinetics Pharmaceuticals, Inc. (CRNX) With Big Upside Post-Approval (Insider Monkey)
04:01AM	JPMorgan Lifts PT on Crinetics Pharmaceuticals (CRNX) to $52 From $53, Keeps an Overweight Rating (Insider Monkey)
Sep-29-25 06:54PM	Crinetics Pharma (CRNX) Flies 35% Higher on FDA Approval of Acromegaly Drug (Insider Monkey) -5.23%
Sep-28-25 08:30AM	Is Crinetics Pharmaceuticals Stock a Buy? (Motley Fool)
Sep-26-25 04:22PM	Crinetics Pharma Surges After FDA OKs Its Treatment For Growth Disorder (Investor's Business Daily) +27.92% -5.23%
01:07PM	FDA Approves Crinetics Pharma's First Daily Pill For Rare Growth Disorder (Benzinga)
09:14AM	Crinetics Pharma Surges After FDA OKs Its Treatment For A Form Of Gigantism (Investor's Business Daily)
Sep-25-25 05:30PM	Crinetics Announces FDA Approval of PALSONIFY (paltusotine) for the Treatment of Adults with Acromegaly (GlobeNewswire)
Sep-10-25 04:30PM	Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
01:21PM	CTSWC25: The future of clinical trial supply hinges on risk management (Clinical Trials Arena)
Aug-21-25 08:45AM	Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH) (GlobeNewswire)
Aug-11-25 04:05PM	Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-07-25 05:55PM	Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-31-25 11:56AM	Crinetics Pharmaceuticals, Inc. (CRNX)' Oral Acromegaly Drug Nears FDA Decision After Strong Phase 3 Data (Insider Monkey)
10:00AM	Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q2 Earnings Expected to Decline (Zacks)
Jul-16-25 09:38AM	Crinetics Pharmaceuticals (CRNX) Gets Initiated With a Hold Rating at Goldman Sachs (Insider Monkey)
Jul-14-25 05:53AM	Crinetics reveals new data from acromegaly therapy programme (Clinical Trials Arena)
Jul-13-25 05:45PM	Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY (Paltusotine) in Acromegaly at ENDO 2025 (GlobeNewswire)
Jul-11-25 08:00AM	Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025 (GlobeNewswire)
Jul-10-25 04:28PM	Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-08-25 08:21AM	Should You Hold Crinetics Pharmaceuticals (CRNX)? (Insider Monkey)
Jul-03-25 08:17AM	Ionis Pharmaceuticals (IONS) Moves 9.1% Higher: Will This Strength Last? (Zacks)
Jun-30-25 04:05PM	Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline (GlobeNewswire)
Jun-16-25 08:00AM	Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025 (GlobeNewswire)
Jun-10-25 04:29PM	Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The firm's product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. It is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

FounderDr. R. Scott Struthers Ph.D.

Co-Founder & Chief Scientific OfficerDr. Stephen F. Betz Ph.D.

Chief Financial OfficerMr. Tobin C. Schilke

Chief Information OfficerMr. Kea Lingo

Head of Investor RelationsMs. Gayathri Diwakar

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Struthers Richard Scott	President & CEO	Aug 07 '26	Option Exercise	20.07	19,928	399,988	424,706	Aug 11 04:11 PM
Vivaldi Coelho Rogerio	Director	Jul 02 '26	Sale	40.00	3,000	120,000	19,225	Jul 07 04:30 PM
JEFF KNIGHT	Officer	Jul 02 '26	Proposed Sale	38.68	47,420	1,834,206		Jul 02 04:31 PM
ROGERIO VIVALDI COELHO	Director	Jul 02 '26	Proposed Sale	38.68	6,000	232,080		Jul 02 04:29 PM
Okey Stephanie	Director	Jun 17 '26	Sale	35.67	6,900	246,143	6,400	Jun 18 05:23 PM
STEPHANIE OKEY	Director	Jun 17 '26	Proposed Sale	35.00	6,900	241,500		Jun 17 04:27 PM
JEFF KNIGHT	Officer	May 04 '26	Proposed Sale	39.02	9,485	370,105		May 04 04:26 PM
JEFF KNIGHT	Officer	Apr 14 '26	Proposed Sale	38.66	20,900	807,994		Apr 14 04:37 PM
JEFF KNIGHT	Officer	Apr 13 '26	Proposed Sale	39.44	4,434	174,877		Apr 13 04:36 PM
Knight Jeff E.	Chief Dev. & Operating Officer	Apr 08 '26	Option Exercise	22.42	78,434	1,758,818	190,452	Apr 10 04:33 PM
Knight Jeff E.	Chief Dev. & Operating Officer	Apr 08 '26	Sale	40.10	85,163	3,415,036	105,289	Apr 10 04:33 PM
JEFF KNIGHT	Officer	Apr 08 '26	Proposed Sale	38.41	85,163	3,271,111		Apr 08 04:49 PM
Knight Jeff E.	Chief Operating Officer	Mar 16 '26	Sale	37.37	9,911	370,411	112,018	Mar 18 05:13 PM
Betz Stephen F.	Chief Scientific Officer	Mar 16 '26	Sale	37.37	10,612	396,610	137,101	Mar 18 05:11 PM
Struthers Richard Scott	President & CEO	Mar 16 '26	Sale	37.37	21,981	821,513	404,778	Mar 18 05:05 PM
DANA PIZZUTI	Officer	Mar 18 '26	Proposed Sale	37.89	24,756	938,005		Mar 18 04:30 PM
Jeff Knight	Officer	Mar 16 '26	Proposed Sale	37.49	25,113	941,486		Mar 16 09:24 AM
Stephen Betz	Officer	Mar 16 '26	Proposed Sale	37.49	26,525	994,422		Mar 16 09:23 AM
Richard Scott Struthers	Director	Mar 16 '26	Proposed Sale	37.49	45,013	1,687,537		Mar 16 09:23 AM
Vivaldi Coelho Rogerio	Director	Mar 12 '26	Sale	36.15	5,000	180,761	16,300	Mar 13 05:46 PM
ROGERIO VIVALDI COELHO	Director	Mar 12 '26	Proposed Sale	36.98	5,000	184,900		Mar 12 04:28 PM
Okey Stephanie	Director	Mar 03 '26	Sale	39.67	3,000	119,010	13,300	Mar 04 05:44 PM
Schilke Tobin	Chief Financial Officer	Mar 03 '26	Sale	39.67	6,713	266,305	78,121	Mar 04 05:43 PM
STEPHANIE S OKEY	Director	Mar 03 '26	Proposed Sale	40.68	3,000	122,040		Mar 03 04:32 PM
Tobin Schilke	Officer	Mar 02 '26	Proposed Sale	41.18	6,800	280,000		Mar 02 10:28 AM
DANA PIZZUTI	Officer	Feb 02 '26	Proposed Sale	49.94	10,000	499,400		Feb 02 04:32 PM
Kalofonos Isabel	Chief Commercial Officer	Jan 05 '26	Option Exercise	40.59	2,500	101,475	3,334	Jan 07 05:11 PM
Kalofonos Isabel	Chief Commercial Officer	Jan 05 '26	Sale	55.00	2,500	137,500	834	Jan 07 05:11 PM
ISABEL KALOFONOS	Officer	Jan 05 '26	Proposed Sale	46.73	2,500	116,825		Jan 05 04:43 PM
DANA PIZZUTI	Officer	Jan 02 '26	Proposed Sale	46.55	5,000	232,750		Jan 02 04:31 PM
Betz Stephen F.	Chief Scientific Officer	Dec 26 '25	Option Exercise	1.91	18,000	34,380	117,713	Dec 29 04:36 PM
Struthers Richard Scott	President & CEO	Dec 18 '25	Option Exercise	13.09	44,742	585,890	364,759	Dec 18 06:54 PM
Pizzuti Dana	Chief Med and Dev Officer	Dec 01 '25	Option Exercise	16.89	5,000	84,450	71,837	Dec 03 04:28 PM
Pizzuti Dana	Chief Med and Dev Officer	Dec 01 '25	Sale	45.02	5,000	225,100	66,837	Dec 03 04:28 PM
DANA PIZZUTI	Officer	Dec 01 '25	Proposed Sale	45.56	5,000	227,800		Dec 01 04:37 PM
Pizzuti Dana	Chief Med and Dev Officer	Nov 03 '25	Option Exercise	16.89	5,000	84,450	71,270	Nov 05 05:00 PM
Pizzuti Dana	Chief Med and Dev Officer	Nov 03 '25	Sale	42.66	5,000	213,312	66,270	Nov 05 05:00 PM
DANA PIZZUTI	Officer	Nov 03 '25	Proposed Sale	43.50	5,000	217,500		Nov 03 04:26 PM
Pizzuti Dana	Chief Med and Dev Officer	Oct 01 '25	Option Exercise	16.89	5,000	84,450	71,270	Oct 03 04:41 PM
Pizzuti Dana	Chief Med and Dev Officer	Oct 01 '25	Sale	41.81	5,000	209,050	66,270	Oct 03 04:41 PM
DANA PIZZUTI	Officer	Oct 01 '25	Proposed Sale	41.65	5,000	208,250		Oct 01 04:30 PM
Struthers Richard Scott	President & CEO	Sep 26 '25	Sale	45.00	4,000	180,000	106,000	Sep 30 04:42 PM
Fust Matthew K	Director	Sep 26 '25	Option Exercise	1.91	10,000	19,100	38,836	Sep 30 04:41 PM
Fust Matthew K	Director	Sep 26 '25	Sale	44.75	16,000	716,000	22,836	Sep 30 04:41 PM
MATTHEW K FUST	Director	Sep 26 '25	Proposed Sale	35.89	16,000	574,240		Sep 26 04:27 PM
Struthers Richard Scott	Officer	Sep 26 '25	Proposed Sale	45.00	4,000	180,000		Sep 26 04:09 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CRNX

Crinetics Pharmaceuticals Inc

Upgrade your Finviz experience